Objectives. SLE is an autoimmune disease with increased cardiovascular morbidity and
platelet activation. In the general population, increased platelet size predicts platelet …

Introduction Systemic lupus erythematosus (SLE) is a connective tissue disease that is
chronic, recurrent and multisystem with unknown aetiology. There is still no single biomarker …

Objective Platelet activation is a possible pathogenic process contributing to
thromboembolism in antiphospholipid syndrome (APS), and platelet distribution width …

Dysregulation of lymphocyte function, accumulation of autoantibodies and defective
clearance of circulating immune complexes and apoptotic cells are hallmarks of systemic …

Currently, many studies have focused on the possibility of using mean platelet volume
(MPV) as a biomarker for disease activity in patients with systemic lupus erythematosus …

Methods: This is a cross-sectional study in which 81 patients with SLE according to the
American College of Rheumatology (ACR) diagnostic classification criteria and 58 healthy …

Background: Significance of platelet distribution width (PDW) and mean platelet volume
(MPV) in assessing disease activity of systemic lupus erythematosus (SLE) remains unclear …

Purpose of review Current knowledge on the role of platelets and platelet-derived
microparticles (PMPs) on the immune system has been fast-growing. Systemic lupus …

Objective—Systemic lupus erythematosus (SLE) is associated with the premature
development of cardiovascular disease. The platelet–endothelium interaction is important in …

Rheumatoid arthritis (RA) is one of the most common chronic inflammatory disorders
associated with enhanced cardiovascular morbidity and mortality. Established high …